Formoterol is More Effective Than Salmeterol in Suppressing Neutrophil Reactivity

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2016 Oct 13

PMID 27730134

Citations 1

Authors

Gregory R Tintinger

Annette J Theron

Helen C Steel

Charles Feldman

Ronald Anderson

Affiliations

Soon will be listed here.

Abstract

http://ow.ly/Qr9fE.

Citing Articles

Fixed-dose combination fluticasone/formoterol for asthma treatment in a real-world setting: meta-analysis of exacerbation rates and asthma control.

Papi A, Qasuri M, Chung E, Abdelbaset M, Aly Moussa M, Backer V Eur Clin Respir J. 2023; 10(1):2174642.

PMID: 36815940 PMC: 9930770. DOI: 10.1080/20018525.2023.2174642.

References

Hoenderdos K, Condliffe A . The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2013; 48(5):531-9. DOI: 10.1165/rcmb.2012-0492TR. View

Kew K, Dias S, Cates C . Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014; (3):CD010844. PMC: 10879916. DOI: 10.1002/14651858.CD010844.pub2. View

Akamatsu T, Shirai T, Kato M, Yasui H, Hashimoto D, Fujisawa T . Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma. Pulm Pharmacol Ther. 2013; 27(1):52-6. DOI: 10.1016/j.pupt.2013.04.001. View

Barnes P . New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol. 2007; 119(5):1055-62. DOI: 10.1016/j.jaci.2007.01.015. View

Mortaz E, Rad M, Johnson M, Raats D, Nijkamp F, Folkerts G . Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J Mol Med (Berl). 2008; 86(9):1045-56. PMC: 2517086. DOI: 10.1007/s00109-008-0360-0. View

de Coupade C, Gear R, Dazin P, Sroussi H, Green P, Levine J . Beta 2-adrenergic receptor regulation of human neutrophil function is sexually dimorphic. Br J Pharmacol. 2004; 143(8):1033-41. PMC: 1575953. DOI: 10.1038/sj.bjp.0705972. View

Hojo M, Iikura M, Hirashima J, Suzuki M, Sugiyama H . A comparison of long-term anti-inflammatory effect of two ICS/LABA combination inhalers; fix-dosed maintenance therapy with budesonide/formoterol and salmeterol/fluticasone. Allergol Int. 2014; 63(1):103-11. DOI: 10.2332/allergolint.13-OA-0590. View

Hozawa S, Terada M, Hozawa M . Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid.... Pulm Pharmacol Ther. 2014; 27(2):190-6. DOI: 10.1016/j.pupt.2013.12.003. View

Gravett C, Theron A, Steel H, Tintinger G, Cockeran R, Feldman C . Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. Eur Respir J. 2010; 36(6):1417-24. DOI: 10.1183/09031936.00157409. View

10.

Blais L, Forget A, Ramachandran S . Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency.... Clin Ther. 2010; 32(7):1320-8. DOI: 10.1016/j.clinthera.2010.06.022. View

11.

Profita M, Bonanno A, Montalbano A, Albano G, Riccobono L, Siena L . β₂ long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta. 2012; 1822(7):1079-89. DOI: 10.1016/j.bbadis.2012.03.002. View

12.

Kato G, Takahashi K, Tashiro H, Kurata K, Shirai H, Kimura S . β2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells. BMC Immunol. 2014; 15:39. PMC: 4228181. DOI: 10.1186/s12865-014-0039-y. View

13.

Sharafkhaneh A, Mattewal A, Abraham V, Dronavalli G, Hanania N . Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis. 2010; 5:357-66. PMC: 2962302. DOI: 10.2147/COPD.S4215. View

14.

Larsson K, Janson C, Lisspers K, Jorgensen L, Stratelis G, Telg G . Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013; 273(6):584-94. DOI: 10.1111/joim.12067. View

15.

Calverley P, Anderson J, Celli B, Ferguson G, Jenkins C, Jones P . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-89. DOI: 10.1056/NEJMoa063070. View

16.

Wex E, Kollak I, Duechs M, Naline E, Wollin L, Devillier P . The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation. Br J Pharmacol. 2015; 172(14):3537-47. PMC: 4507158. DOI: 10.1111/bph.13143. View

17.

Theron A, Steel H, Tintinger G, Feldman C, Anderson R . Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?. Drug Des Devel Ther. 2013; 7:1387-98. PMC: 3840775. DOI: 10.2147/DDDT.S50995. View

18.

Lambers C, Qi Y, Eleni P, Costa L, Zhong J, Tamm M . Extracellular matrix composition is modified by β₂-agonists through cAMP in COPD. Biochem Pharmacol. 2014; 91(3):400-8. DOI: 10.1016/j.bcp.2014.07.026. View

19.

Strandberg K, Blidberg K, Sahlander K, Palmberg L, Larsson K . Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Pulm Pharmacol Ther. 2010; 23(4):316-23. DOI: 10.1016/j.pupt.2010.03.004. View

20.

Anderson R, Theron A, Steel H, Durandt C, Tintinger G, Feldman C . The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro. Mediators Inflamm. 2014; 2014:105420. PMC: 3964838. DOI: 10.1155/2014/105420. View